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the expected annual number of cervical cancer cases (CC) and deaths prevented by HPV 
vaccination of 12-year-old girls in Asian countries (WHO classes) at steady state. Input 
data are, for each country, the incident CC cases and deaths (GLOBOCAN 2002), the 
distribution of HPV types in CC (http://www.who.int/hpvcentre) and the clinical trial 
vaccine efﬁ cacy against CIN2+ related to HPV-16/18 and HPV-31,45,33,52,58,35,
39,51,56,59 combined (cross-protection). Lifetime vaccine protection is assumed. The 
effect of vaccination coverage and the use of alternative estimates for countries without 
sufﬁ cient data are explored. RESULTS: Of 47 countries, sufﬁ cient country-speciﬁ c input 
data are available for eight (China, Japan, Iran, Indonesia, Republic of Korea, Thailand 
and Philippines). The model predicts that, with 100% vaccine coverage, the HPV-16/18 
CC and death reduction ranges from 57% (Japan: −4421 cases; −2032 deaths) to 74% 
(Thailand: −4627 cases; −1942 deaths) while cross-protection related CC and death 
reduction ranges from 9% (Iran; −102 cases, −53 deaths) to 27% (Japan; −2073 cases; 
−953 deaths). The overall reduction ranged from 78% (Iran: −873 cases, −454 deaths) 
to 89% (Indonesia: −13,375 cases; −6724 deaths; Thailand −5534 cases; −2323 deaths). 
With 70% vaccine coverage the CC cases prevented ranges from 611 to 80,052 and CC 
deaths prevented from 318 to 44,921 for Iran and India respectively. Eastern, south-
eastern, southern Asia and Asia continent distributions are available and can be used as 
a proxy for countries without sufﬁ cient HPV data. CONCLUSIONS: Modeling predicts 
HPV vaccination with a bivalent HPV-16/18 vaccine could result in substantial reduc-
tions in CC cases and deaths in Asian countries. Cross-protection could play an impor-
tant role in this reduction. 
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OBJECTIVES: To undertake an economic evaluation of the costs and outcomes of 
midwifery group practice care compared with usual care in an Australian metropolitan 
hospital. METHODS: In a cohort study, pregnant women at low risk of complications 
could select to receive midwifery group practice care or usual care early in their 
pregnancy and were recruited when they were 35 weeks pregnant. Midwifery group 
practice provides care by the same two to three midwives and labor in a birth center. 
Usual care consists of women generally attending a GP or midwives antenatal clinic 
for antenatal care, followed by labor in the hospital. Costing data was collected from 
week 36 of pregnancy until 6 weeks postpartum. Costing for antenatal, labor, baby, 
and postnatal care were collected using the hospital accounting system. Women kept 
a diary with the number of antenatal and postnatal visits. Costing data on GP visits 
were calculated using the diaries and government reimbursement costs. RESULTS: 
The study included 102 women, with 52 women receiving midwifery group practice 
care and 50 women receiving usual care. Midwifery group practice care was associated 
with fewer antenatal visits, lower rate of induction and pharmacological pain relief, 
shorter stay in hospital and more postnatal visits. There were no statistical differences 
in clinical outcomes of the baby. The cost of antenatal care was similar between the 
groups; labor and baby costs were lower for midwifery group practice, while postnatal 
costs were higher in the midwifery group practice. Midwifery group practice was 
associated with a lower total cost per woman compared to usual care (A$4447 vs. 
A$5772, P = 0.047). CONCLUSIONS: For women at low risk of complications 
midwifery group practice is a cost-effective option, with better clinical outcomes and 
lower total costs. 
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OBJECTIVES: Childhood immunizations are recognized as one of the most cost-
effective health interventions. Yet little is know about the actual delivery costs, or 
variation in costs by service providers and geographic regions. This study undertook 
an economic analysis of public health delivery of childhood immunizations in Nova 
Scotia. METHODS: The analysis was performed from the perspective of the govern-
ment health-care provider for a 1-year period from April 2005 to March 2006. An 
incremental approach was used to assess the cost of delivering childhood immuniza-
tions in addition to existing services. Primary cost data collected included capital and 
recurrent costs. Total provider economic costs were estimated using a combination of 
ingredients-based costing and step-down cost allocation methodologies. Sensitivity 
analysis was used to examine the inﬂ uence of data uncertainty on cost results. Mul-
tivariate econometric analysis was used to estimate cost functions. RESULTS: Data 
was collected from four District Health Authorities in Nova Scotia, representing the 
delivery of 2951 immunizations. Average cost per immunization ranged from $51 to 
$105 when delivered in main public health ofﬁ ces and $45 to $150 when delivered 
in off-site clinics. The main cost driver was personnel costs. Econometric analysis 
showed a link between average cost and volume of service delivery. CONCLUSIONS: 
The cost of public health delivery of childhood vaccines varies according to the volume 
of services delivered and the delivery setting. The approach developed can be applied 
to the introduction of new vaccines such as human papilloma virus. Public health 
delivery of vaccines can be efﬁ cient if programmed on the appropriate scale. 
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OBJECTIVES: To investigate medical cost and health resource utilization for patients 
with postpartum hemorrhage (PPH) in Korea in 2008. METHODS: This population-
based study utilized the claims data of the Korea Health Insurance Review Agency 
from January 2008 to December 2008. Patients with PPH were identiﬁ ed based on 
ICD-10 code (O72, O721, O722, O723) that occurred within 6 weeks after normal 
or cesarean delivery. Treatments for PPH were classiﬁ ed into four categories: uterine 
contraction drugs only, drugs and transfusion, drugs + transfusion + uterine artery 
embolization (UAE), and drugs + transfusion + hysterectomy. Medical costs for PPH 
patients included all costs incurred for delivery and treating PPH. Costs and length of 
stay were analyzed in regard to the mode of delivery, age, and type of hospital where 
the delivery took place. Data were analyzed using SAS. RESULTS: There were 18,142 
(4%) PPH patients out of 452,219 deliveries in Korea in 2008. The medical cost (mean 
± SD) in patients who underwent normal delivery (ND) without PPH was 610 ± 153 
US$ and 758 ± 859 US$ for patients with PPH. The medical cost in patients who 
underwent cesarean delivery (CD) without PPH was 973 ± 1403 US$ and 860 ± 511 
US$ for patients with PPH. Length of stays (mean ± SD) were 3.7 ± 1.8 days, 3.3 ± 
0.7 days, 7.7 ± 8.8 days and 7.1 ± 3.2 days for ND with PPH patients, ND without 
PPH patients, CD with PPH patients, and CD without PPH patients, respectively. The 
mean medical cost of patients who were treated with drugs only, drugs and transfu-
sion, drugs + transfusion + UAE, and drugs + transfusion + hysterectomy were 
US$628, US$1028, US$3850, and US$3501, respectively. CONCLUSIONS: The 
medical cost was higher in patients with PPH compared to patients without PPH. 
Although the medical cost of treating PPH with UAE is higher than that of hysterec-
tomy, preserving fertility seems well worth the additional cost. 
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BACKGROUND: Liver transplantation in children is an expensive health service 
excluded from the beneﬁ t package of the universal coverage (UC) scheme, which 
covers 47 million of Thais. Its high costs and exclusion from the UC beneﬁ t package 
prevent poor biliary atresia (BA) patients from access to such health care. OBJEC-
TIVES: This study aims to estimate ﬁ nancial impact of including liver transplantation 
in children in the UC beneﬁ t package. It also explores demand for, and supply of, and 
ﬁ nancial feasibility in implementing universal access to such expensive health care in 
Thailand. METHODS: Methods include comprehensive literature review, in-depth 
interviews of medical specialists in liver transplantation in three university hospitals 
about incurred costs during and after operations, and modeling budget requirements 
for expanding universal access to such medical care. RESULTS: Research ﬁ ndings 
indicate that the incidence of BA patients in Thailand is approximately 1 to 15,000 
of live births, approximately 60 new cases of BA patient annually. Only three univer-
sity hospitals in Thailand can provide liver transplantation to children with the annual 
maximum surgical capacity of 40 cases. Literature shows the survival rate of BA 
children receiving liver transplantation ranges from 83% to 94% in the ﬁ rst year, and 
82% to 92% in the ﬁ fth year. Costs of liver transplantation in the ﬁ rst year are 
approximately 1 million Baht (US$30,000). Other costs after the ﬁ rst year including 
immunosuppressive drugs and prophylaxis antibiotics range from US$360–600 per 
month. The government will spend approximately 40 million Baht in the ﬁ rst year of 
implementation. The ﬁ nancial burden will increase to 184 and 328 million Baht per 
year in the year 30th and 70th, respectively. CONCLUSIONS: The budget require-
ment for this medical care is trivial compared to the total UC budget, but can save 
lives of BA patients and improve equity in access to health care. 
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OBJECTIVES: Cervical cancers are the second highest incidence of female cancers in 
Malaysia, causing high impact on nation’s health cost and patient’s quality of life that 
can be avoided by better screening and HPV vaccination. METHODS: This is a cross 
sectional study done from 2006–2009 and respondents were interviewed from six 
public hospitals. Methods include experts’ panel discussions to estimate treatment 
costs and respondents’ interviews using costing and SF-36 quality of life (QOL) 
questionnaires. Three programs options were compared i.e., Pap smear screening; 
quadrivalent HPV vaccination and combined strategy (screening plus vaccination). 
RESULTS: Five hundred two cervical cancer patients participated in the study. Mean 
